Is Regeneron Stock a Bargain Below $800?

Regeneron posted Q2 revenue growth of 17% year over year to $4.3 billion, supported by Dupixent global sales growth of 38% to $6.0 billion. Eylea franchise sales remained under pressure, with combined U.S. Eylea and Eylea HD revenue down 12% to roughly $1.0 billion, but Eylea HD sales rose 52% to $596 million as it offsets biosimilar erosion in the legacy product. The company’s pipeline, including obesity candidate olatorepatide, which delivered up to 19% weight loss over 48 weeks in a China Phase 3 trial, and its dividend and buyback programs support a constructive long-term outlook despite patent and clinical-regulatory risks.

Analysis

The key investable question is whether the retinal franchise has reached a manageable erosion rate, not whether the higher-dose conversion can produce another quarter of favorable mix. A successful conversion protects realized revenue per patient and may reduce switching, but payer formulary changes and biosimilar rebates can still accelerate volume attrition after the initial transition. The next 1-3 months should focus on U.S. retinal prescription share, net-price trends, and whether management can hold full-year franchise guidance without relying on one-time inventory or channel effects.

REGN's multiple can re-rate if investors gain confidence that immunology cash flows more than offset ophthalmology runoff, but the economic exposure is not identical for SNY: Dupixent creates a cleaner growth offset for Sanofi, while Regeneron retains greater sensitivity to the pace of Eylea franchise decay. That makes REGN a higher-beta expression of a favorable execution outcome, whereas SNY is the lower-volatility way to own continued Dupixent expansion. A material downside trigger would be a sequential slowdown in Dupixent demand, a sharper-than-expected Eylea net-sales decline, or evidence that HD adoption is largely cannibalistic rather than retaining patients who would otherwise switch.

The obesity asset is strategically interesting but should receive little near-term valuation credit. Chinese late-stage efficacy is not directly transferable to U.S. regulatory approval, tolerability, manufacturing scale, reimbursement, or differentiation against entrenched Lilly and Novo Nordisk products; a muscle-preservation combination could be more commercially differentiated, but is a 6-18 month clinical-development catalyst at best. Consensus may be too optimistic on a seamless Dupixent lifecycle extension as well: a reformulation only preserves value if physicians, payers, and regulators view its dosing or clinical profile as sufficiently differentiated to prevent rapid substitution at loss of exclusivity.

Key Decisions for Investors

• Maintain a modest long REGN only after confirming the next earnings release preserves or raises full-year guidance while retinal-franchise decline remains at or better than the recent run rate. Target a 6-12 month holding period; cut if management lowers guidance because of Eylea pricing or share losses, since that would undermine the central cash-flow bridge thesis.
• For lower-volatility immunology exposure, prefer SNY over REGN until U.S. Eylea HD share, biosimilar contracting, and net-price data demonstrate stabilization. This is not a clean pair trade because SNY has substantial non-Dupixent drivers, but it reduces single-franchise ophthalmology risk over the next 1-3 quarters.
• Do not underwrite meaningful value for olatorepatide before U.S./global development design, safety disclosure, manufacturing strategy, and competitive positioning versus LLY and NVO are available. Set an alert for first material U.S. clinical or regulatory update; positive Chinese data alone is insufficient basis for an options position.
• Watch RHHBY retinal-market share and dosing-interval data as an external read-through on REGN. A sustained share gain for Vabysmo or aggressive anti-VEGF contracting would favor reducing REGN exposure even if headline HD revenue growth remains strong.